• LevelJump Healthcare Corp. (JUMP) has announced a non-brokered private placement to raise gross proceeds of up to $10,000,000
  • The company will issue up to 10,000,000 units at $1.00 per unit
  • Each unit will consist of one common share and one Class A Series 1 preferred share
  • The offering is expected to close in November 2022
  • Leveljump Healthcare is a healthcare company
  • LevelJump Healthcare Corp. (JUMP) is unchanged on the day, trading at C$0.085 per share at 1:30 pm ET

LevelJump Healthcare Corp. (JUMP) has announced a non-brokered private placement to raise gross proceeds of up to $10,000,000.

The company will issue up to 10,000,000 units at $1.00 per unit. Each unit will consist of one common share and one 8 per cent redeemable convertible Class A Series 1 preferred share.

Each preferred share is non-voting and carries a cumulative annual dividend of 8 per cent, payable quarterly. 

The offering is expected to close in November 2022 and is conditional upon receipt of all required regulatory approvals.

All securities issued will be subject to a statutory four-month hold period.

Leveljump Healthcare is a healthcare company with a focus on profitable telehealth solutions as well as primary care services in radiology. The company provides radiology solutions for hospitals, emergency rooms, and private clinics.

LevelJump Healthcare Corp. (JUMP) is unchanged on the day, trading at C$0.085 per share at 1:30 pm ET.


More From The Market Online

Dream Water Kids Sleep Gummies set for US summer debut

Delivra Health (TSXV:DHB) will launch a new line of kids sleep gummies under its Dream Water brand across the US market this June.

Buzz on the Bullboards: Oil shock, biotech breakthroughs and new tech

Global equities lurched from rally to rout since the U.S.–Israel strikes on Iran ignited a regional war and shutdown of the Strait of Hormuz.

Quit smoking with psychedelics? A new frontier for treatment — and investors

A new Johns Hopkins study found that a single dose of psilocybin, combined with therapy, helped smokers stay cigarette free at six months.

New bladder cancer drug may sharpen radiation’s aim

Theralase Technologies proves that its Rutherrin drug holds the potential to enhance radiation against non-muscle invasive bladder cancer.